Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile

Show simple item record

dc.contributor.author Cassani, E.
dc.contributor.author Cilia, R.
dc.contributor.author Laguna, J.
dc.contributor.author Barichella, M.
dc.contributor.author Contin, M.
dc.contributor.author Cereda, E.
dc.contributor.author Isaias, I.U.
dc.contributor.author Sparvoli, F.
dc.contributor.author Akpalu, A.
dc.contributor.author Budu, K.O.
dc.contributor.author Scarpa, M.T.
dc.contributor.author Pezzoli, G.
dc.date.accessioned 2019-02-13T12:10:47Z
dc.date.available 2019-02-13T12:10:47Z
dc.date.issued 2016-06
dc.identifier.other Volume 365,Pages 175-180
dc.identifier.other https://doi.org/10.1016/j.jns.2016.04.001
dc.identifier.uri http://ugspace.ug.edu.gh/handle/123456789/27495
dc.description.abstract Background Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. Methods We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations. Results Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD + DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. Conclusion Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD + DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries. © 2016 The Authors. en_US
dc.language.iso en en_US
dc.publisher Journal of the Neurological Sciences en_US
dc.subject Levodopa en_US
dc.subject Mucuna pruriens en_US
dc.subject Parkinson's disease en_US
dc.title Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UGSpace


Browse

My Account